feedback

Course Director

Roy H. Decker, MD, PhD
Roy H. Decker, MD, PhD

Yale School of Medicine
New Haven, Connecticut

Faculty

Sarah B. Goldberg
Sarah B. Goldberg, MD, MPH

Yale School of Medicine
New Haven, Connecticut

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME
Credit Amount:1.5 Credits
Release Date:2018-Dec-07
Expiration Date:2019-Dec-06
Estimated Time for Completion:90 minutes
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

In this activity, experts in non–small cell lung cancer (NSCLC) discuss the rationale for the use of cancer immunotherapies in earlier stages of lung cancer, the implications of the most recent data supporting the integration of immune checkpoint inhibitor therapy into the multimodal treatment of stage III NSCLC, and which patients with stage III lung cancer are the best candidates for immunotherapy. In addition, the experts also discuss several practical issues related to the use of immunotherapy in stage III NSCLC, including the timing of immunotherapy administration and the recognition and management of immune-related adverse reactions (IMARs).

Upon completion of this activity, participants should be better able to:
  • Describe how to harness the immune system in the treatment of cancer, mechanisms of action of the immune checkpoint inhibitors, and rationale for use of immunotherapy in stage III NSCLC as well as other earlier disease stage settings of lung cancer
  • Discuss key clinical data on the efficacy and safety of checkpoint inhibitor-based treatment of patients with stage III, locally advanced, unresectable NSCLC whose cancer has not progressed following chemoradiation therapy
  • Summarize other key clinical trials evaluating immunotherapies and immunotherapy-based combinatorial approaches in earlier stages of lung cancer
  • Identify appropriate patients with locally advanced, unresectable NSCLC who are candidates for immunotherapy as part of multimodal therapy for stage III disease
  • Develop an optimal multimodal treatment plan inclusive of chemoradiation and consolidation immunotherapy for appropriate patients with stage III NSCLC, considering the latest evidence, indications, recommendations, and patient needs/preferences
  • Manage overlapping and non-overlapping adverse effects associated with immunotherapy, radiation therapy, and chemotherapy in patients with stage III NSCLC receiving consolidation therapy with a checkpoint inhibitor following chemoradiation

Target Audience

This activity has been designed to meet the educational needs of radiation oncologists, medical oncologists, and other clinicians involved in the management of patients with lung cancer.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: December 07, 2018 - December 06, 2019
Time to Complete: 90 minutes

Faculty and Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity during the past 12 months.

Course Director and Moderator

Roy H. Decker, MD, PhD
Professor & Vice Chair
Director of Clinical Research
Department of Therapeutic Radiology
Yale School of Medicine
New Haven, Connecticut

Roy H. Decker, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Merck & Company, Inc.
Speakers Bureau participant with AstraZeneca.
Advisory Board for AstraZeneca; Merck & Company, Inc.; and Regeneron Pharmaceuticals, Inc.

Roy H. Decker, MD, PhD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: Immune checkpoint inhibitors as monotherapies or as part of combinations.

Faculty

Sarah B. Goldberg, MD, MPH
Assistant Professor of Medicine (Medical Oncology)
Yale School of Medicine
New Haven, Connecticut

Sarah B. Goldberg, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Advisory Board for AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb; Eli Lilly and Company; and Genentech, Inc.

Sarah B. Goldberg, MD, MPH, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: Immune checkpoint inhibitors as monotherapies or as part of combinations.

CME Reviewer

Vishwanath Sathyanarayanan, MD, DM

Vishwanath Sathyanarayanan, MD, DM, has no financial interests/relationships or affiliations in relation to this activity.

Medical Directors

Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

Kadrin Wilfong, MD
PVI, PeerView Institute for Medical Education

Kadrin Wilfong, MD, has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit, and Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Providership


This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by an independent educational grant from AstraZeneca.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

Copyright © 2000-2018, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.